Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000919574-25-001404
Filing Date
2025-02-14
Accepted
2025-02-14 10:42:33
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 16314
2 d11606173_ex99-i.htm EX-99 10216
  Complete submission text file 0000919574-25-001404.txt   28269
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Subject) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90539 | Film No.: 25624678
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 2828 N HARWOOD STREET SUITE 1220 DALLAS TX 75201
Business Address 2828 N HARWOOD STREET SUITE 1220 DALLAS TX 75201 214-550-1822
Avidity Partners Management LP (Filed by) CIK: 0001791827 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A